Human-Centric Marketing is the current trend in marketing that looks at customers holistically, recognizing their emotions as one of the most important dimensions. All experts indicate that only the companies that adapt to this trend will successfully survive the current competitive and global environment. However, traditional market methodologies cannot objectively measure emotional insights as this information is unconscious and cannot be accessed under rational processes. BitBrain has already developed a neurotechnology solution able to measure emotions completely adapted to the market research sector, and the objective of the usenns project is to penetrate the market. This solution has 3 main innovations: i) two new measurement devices (neuroheadset and a “ring”) adapted to the market research sector; ii) the encapsulation and integration within the technology of all the neuroscience knowledge on design-execution of experiments and on elaborated data analysis, in a completely transparent manner for the user; and iii) presentation of the results on emotions of consumers in a comprehensible and valuable language for the market researcher and its client. This results in a technology easy to implement in market research companies without incurring a risk due to high initial investments (clients pay an affordable price for the measurement devices), and a pay-per-use with a reasonable price only charged at the end of a study. This pay-per-use service with a visualization and interaction web-based application make this business model highly scalable. The objectives of the feasibility project are to accelerate the process of corroborating the business plan, and to define an action plan to reach mainstream commercial use from the current prototype state. After the feasibility study, the action plan will bring to the market a solution that will revolutionize the global market research sector by helping companies to design better strategies adapted to their customers

Problem. Dementia is a major public health issue, with no effective, efficient, or safe treatments currently available to cure or delay its onset. Breakthrough. Elevvo offers a groundbreaking solution, becoming the first validated medical device to treat mild cognitive impairment (MCI) and delay the onset of dementia. This breakthrough is based on the combination of two innovative treatments that combine neurotechnology and artificial intelligence (AI). The first treatment utilizes active neuromodulation, while the second involves passive auditory stimulation during sleep. Innovation. Elevvo introduces a new standard in neuro-therapeutics, with two evidence-based treatments that can be self-managed at home, with remote supervision by physicians. Key components are: 1) HomeKit: A user-friendly neuroheadset paired with a mobile tablet, equipped with 4G/5G connectivity for delivering AI-driven treatments. 2) Cloud-based software: A system to manage treatments and a web-based portal, allowing physicians to monitor patient progress remotely. Current State. In Phase 1 and Phase 2a clinical trials, Elevvo demonstrated that patients could safely and independently use the HomeKit. Both treatments also showed significant improvements in biomarkers related to working memory, episodic memory, and memory consolidation in the target population (MCI patients). The results have qualified for a multicenter randomized clinical trial Phase 2b clinical trial currently under execution. Path Forward. Support from the EIC will enable the progression from TRL 6 to 9, culminating in international multicenter Phase 3 clinical trials, scaling up, and moving towards the go-to-market phase.

Cognitive decline (progressive loss of mental cognitive abilities) is a natural event that affects us all after the age of 40. Although age is a main factor, low-demanding brain activity can speed up the process & end up in cognitive impairment, which is a major cause of disability worldwide. Importantly, the onset & progress of cognitive decline can be hindered with preventive training that stimulates cognitive abilities. This realization is driving the market of cognitive training, foreseeing a $7.5 billion turnover and 83% population adoption by 2020. This growth will be mostly driven by the revolution of wearables & biometric technologies, which are increasing rapidly as people become more prone to manage their own health. However, current market offerings for brain training either need the presence of a clinical specialist or lack any scientific relevance. In response, we at BitBrain Technologies have developed ELEVVO, a ground-breaking neuro-wearable technology that enables self-management of cognitive welfare and yields real measurable enhancement. ELEVVO uses a gaming approach to train cognitive-related patterns, relying on intelligent big-data mining to automatically tailor the challenges to the users’ brain rhythms and to measure the progress achieved. Importantly, ELEVVO will be the only scientifically-validated product for cognitive training in the mass market. Indeed, we have proved the ELEVVO’s efficiency in healthy adults (students, workers, elderly) and in neuropathology cases. Altogether, with this project we aim to finalise the development of ELEVVO and to scale-up our deployment capability. The Feasibility Study planned in Phase 1 will help us warrant the project from all technical, commercial & financial standpoints. Upon completion, ELEVVO will bring a major social & economic impact to society, enhancing life-quality & well-being. In turn, it will boost the growth of our company, projecting a R..

30% of adults in industrialized countries such as the United States, United Kingdom, Japan, Germany, and Canada do not get good quality sleep on a regular basis. Insufficient and poor sleep has been declared a "public health problem" as it is associated with a range of negative health and social outcomes, including unsuccess in school and in the labor market. In economic terms, poor sleep - or the lack of it - leads to significant economic losses (up to 411 and 138 B$/year in the US and Japan, respectively), and there is growing evidence indicating a strong association between short sleep duration and high mortality risks. This project explores the implementation of a new neurotechnology to improve sleep quality, aiming to penetrate the Global Sleep Tech Device Market that exceeded USD 9 billion in 2018 and is set to achieve over 16% CAGR by 2025, surpassing USD 27 billion. The novel, consumer-grade device is based on a unique EEG/TCS developed by Bitbrain and is a very recent research breakthrough finding in sleep quality improvement. The rationale of this project is Bitbrain’s need to hire highly qualified personnel in Sleep and EEG/TCS technology to explore this innovation, in combination with the difficulty of the company to access this type of personnel. The impact of the recruitment will be the implementation of a sleep R&D area in the company, and he/she will benefit from working in a very interdisciplinary R&D team with many training possibilities. The specific objectives of the innovation associate will explore the feasibility of employing this new wearable EEG/TCS for sleep quality improvement, evaluate its effectiveness in laboratory settings, and verify the potential to transfer these results to the real world. If successful, this new technology will be the first of its class to potentially impact a very important social issue effectively.

More than half of the persons with spinal cord injuries (SCI) are suffering from impairments of both hands, which results in a tremendous decrease of quality of life (QoL) and represents a major barrier for inclusion in society. Functional restoration is possible with neuroprostheses based on functional electrical stimulation (FES). However, current systems are non-intelligent, non-intuitive open loop systems without sensory feedback. MoreGrasp aims at developing a multi-adaptive, multimodal user interface including brain-computer interfaces (BCIs) for intuitive control of a semi-autonomous motor and sensory grasp neuroprosthesis to support activities of daily living in individuals with SCI. With such a system a bilateral grasp restoration may become reality. The multimodal interfaces will be based on non-invasive BCIs for decoding of movements intentions with gel-less electrodes and wireless amplifiers. The neuroprosthesis will include FES electrode arrays and different sensors to allow for implementation of predefined or autonomously learned sequences. MoreGrasp will consequently follow the concept of the user-centered design by providing a scalable, modular, user-specific neuroprosthesis together with personalized EEG recording technology. Novel multimodal software architectures including interoperability standards will be defined to integrate neuroprostheses into the field of assistive technology. Long-term end user studies will demonstrate the reliability, usefulness and impact on QoL of the MoreGrasp technology. A web-based service infrastructure including a discussion forum will be set up for assessing user priorities and screening of users’ status. The evaluation of the training and patterns of use will allow for user modeling to identify factors for successful use. The highly interdisciplinary MoreGrasp consortium consists of members from universities, industry and rehabilitation centers, which have a long history of successful cooperation.